Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 86
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Rheumatology (Oxford) ; 61(12): 4786-4796, 2022 11 28.
Artículo en Inglés | MEDLINE | ID: mdl-35348643

RESUMEN

OBJECTIVES: To characterize patients with positive anti-topoisomerase I (ATA) in lcSSc. METHODS: SSc patients enrolled in the EUSTAR cohort with a disease duration of ≤3 years at database entry were considered. We assessed the risk of major organ involvement in the following groups: ATA-lcSSc vs ACA-lcSSc and vs ANA without specificity (ANA)-lcSSc, and ATA-lcSSc vs ATA-dcSSc. Cox regression models with time-dependent covariates were performed with the following outcomes: new-onset interstitial lung disease (ILD), ILD progression [forced vital capacity (FVC) decline ≥10% and ≥5% vs values at ILD diagnosis), primary myocardial involvement (PMI), pulmonary hypertension (PH), any organ involvement and all-cause mortality. RESULTS: We included 1252 patients [194 ATA-lcSSc (15.5%)], with 7.7 years (s.d. 3.5) of follow-up. ILD risk was higher in ATA-lcSSc vs ACA- and ANA-lcSSc and similar to ATA-dcSSc, although with less frequent restrictive lung disease. The risk of FVC decline ≥10% (35% of ATA-lcSSc) was lower in ATA-lcSSc than in ATA-dcSSc, whereas FVC decline ≥5% occurs similarly between ATA-lcSSc (58% of patients) and other SSc subsets, including ATA-dcSSc. The risk of PMI was similar in ATA-lcSSc and ANA-lcSSc but lower than in ACA-lcSSc; no difference in PH and mortality risk was observed among lcSSc subsets. The risk of any organ involvement, PMI and PH was lower and the mortality tended to be lower in ATA-lcSSc vs ATA-dcSSc. CONCLUSION: ATA-lcSSc patients have a high risk of ILD, albeit with a lower risk of progression compared with ATA-dcSSc, supporting careful screening for ILD in this subgroup.


Asunto(s)
Hipertensión Pulmonar , Enfermedades Pulmonares Intersticiales , Esclerodermia Difusa , Esclerodermia Limitada , Esclerodermia Sistémica , Humanos , Esclerodermia Difusa/diagnóstico , Enfermedades Pulmonares Intersticiales/etiología , Enfermedades Pulmonares Intersticiales/diagnóstico , Anticuerpos Antinucleares , Hipertensión Pulmonar/etiología , Fenotipo , Esclerodermia Sistémica/diagnóstico
2.
Rheumatol Int ; 41(12): 2195-2203, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34623480

RESUMEN

The hypothesis of the study was that polymorphisms in promoter regions -238 and -308 of TNF-α could be associated with different clinical outcomes in inflammatory bowel diseases (IBD) and immune-mediated rheumatic diseases (IMRD). The aim was to examine the possible association of both polymorphisms with concentration of C-reactive protein (CRP) and fecal calprotectin (fCAL), onset of the remission and development of the ADA in patients on therapy with anti-TNF inhibitors. The prospective study was done in patients with IBD and IMRD on infliximab (IFX) or adalimumab (ADM). Patients were genotyped for TNF-α -238 and -308 polymorphisms. The concentration of CRP, fCAL, IFX or ADM and antibodies to drugs were measured according to manufacturer's instructions and followed-up for 6 or 12 months. Out of all patients (N = 112), number of patients in remission did not differ according to genotypes (for IBD patients P = 0.509 vs 0.223; for IMRD patients P = 0.541 vs 0.132 for TNF-α -238 and -308, respectively). Initial CRP concentration was higher in IBD patients with TNF-α -308 GG than GA/AA genotypes in patients who failed to achieve remission [11.8 (4.4-39.6) vs 3.1 (1.5-6.5), P = 0.033]. In IBD patients with remission, fCAL concentration after at least 6 months of therapy was higher in TNF-α-308 GG than in GA genotype [52 (25-552) vs 20 (20-20) µg/g, P = 0.041]. Our results showed the association of TNF-α -308 GG genotype with a higher concentration of CRP and fecal calprotectin in patients with inflammatory bowel diseases on IFX or ADM therapy. Clinical remission and development of antibodies to anti-TNF drugs were not associated with TNF-α -238 and -308 polymorphisms.


Asunto(s)
Adalimumab/administración & dosificación , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Infliximab/administración & dosificación , Enfermedades Reumáticas/tratamiento farmacológico , Inhibidores del Factor de Necrosis Tumoral/administración & dosificación , Adulto , Anciano , Biomarcadores/análisis , Proteína C-Reactiva/análisis , Femenino , Humanos , Complejo de Antígeno L1 de Leucocito/análisis , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Estudios Prospectivos , Inducción de Remisión , Factor de Necrosis Tumoral alfa
3.
Molecules ; 26(8)2021 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-33920659

RESUMEN

Small-vessel vasculitis (SVV) is the inflammation of the vessel wall that can result in hemorrhage and/or ischemia. Among the histological findings in SVV are increased infiltrating neutrophils, which, due to their oxidative burst and myeloperoxidase activity, release excessive reactive oxygen species, triggering a chain reaction of lipid peroxidation and yielding reactive aldehydes such as acrolein. The implication of oxidative stress in the pathogenesis of SVV was studied, focusing on acrolein immunohistochemistry in the affected skin vessels and systemic stress response. Samples from SVV patients and healthy subjects were collected and analyzed for total serum peroxides, total antioxidant capacity, inflammatory and immunological parameters, as well as for the presence of acrolein-protein adducts in the skin tissue specimens. The obtained data showed that systemic redox homeostasis and iron metabolism are altered in SVV patients. Possible biomarkers in the evaluation of oxidative status, disease activity and prevalence were indicated. Furthermore, a strong correlation between the accumulation of acrolein-protein adducts in the skin and the progression of the disease was revealed. Thus, the results of this study demonstrate that SVV is not only associated with systemic oxidative stress but also with tissue-specific oxidative stress that promotes acrolein formation and protein modification correlating with the severity of cutaneous vasculitis.


Asunto(s)
Acroleína/administración & dosificación , Inflamación/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Vasculitis/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/patología , Femenino , Homeostasis/efectos de los fármacos , Humanos , Inflamación/patología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Persona de Mediana Edad , Peróxidos/metabolismo , Piel/efectos de los fármacos , Piel/patología , Vasculitis/patología
4.
Psychiatr Danub ; 32(Suppl 4): 547-552, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33212462

RESUMEN

BACKGROUND: Rheumatoid arthritis (RA) is a chronic and disabling disease with a great impact on the quality of life (QOL). The aim of this study was to assess QOL and health in RA patients treated with biological disease-modifying drugs (bDMARDs) as opposed to those treated with conventional synthetic DMARDs (csDMARDs). We analysed four domains of QOL: physical health (D1), mental health (D2), social relationships (D3) and one's surroundings (D4); as well as general quality of life (W1), general state of health (W2), and disease activity and physical disability. SUBJECTS AND METHODS: Seventy-seven RA patients (group A=29 on bDMARDs, group B=48 on csDMARDs) were enrolled in the study. QOL was evaluated using WHO questionnaire (WHOQOL-BREF), disease activity using Disease Activity Score 28C-reactive protein (DAS28CRP) and functional status using Health Assessment Questionnaire (HAQ). RESULTS: There was no statistically significant difference of mean values in the four domains of QOL, nor in the general QOL, between groups A and B. There was also no statistically significant difference regarding RA activity (3.51 vrs 3.54, p=0.56). However, we have found that the variable of the general state of health domain was statistically significantly higher in group B (2.66 vrs 2.89, p=0.001), while HAQ was statistically significantly higher in group A (1.19 vrs 1.07, p=0.018), as well as the duration of RA (6.25vrs 3.75 years, p=0.0006). Statistically significant correlation was found between HAQ and W2, disease duration and D3 in group A and DAS28CRP and D1, D2, W2 and HAQ and D1 and D2 in group B. CONCLUSION: These findings suggest that the inclusion of bDMARDs in the treatment regimen was overdue, with RA already advancing with developed functional disability, which prevented the achievement of the primary goals of treatment: low disease activity or remission and the improvement of patient's QOL.


Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/fisiopatología , Medición de Resultados Informados por el Paciente , Calidad de Vida , Adulto , Anciano , Anciano de 80 o más Años , Croacia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios
5.
Acta Clin Croat ; 59(2): 312-317, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33456119

RESUMEN

The aim of this study was to investigate the association of smoking with disease activity, seropositivity, age and gender in patients with rheumatoid arthritis. We included 89 rheumatoid arthritis patients. All patients fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism rheumatoid arthritis classification criteria. Activity of the disease was measured by Disease Activity Score 28-joint count C-reactive protein (DAS28CRP). The subjects were stratified into smoking and non-smoking groups and cross-sectionally analyzed. There were 24 (27%) smokers and 65 (73%) nonsmokers. The mean age of patients was 57.1±8.8 years. The mean DAS28CRP was 5.81 in the smoking group and 5.57 in the non-smoking group, without statistically significant difference between the two groups (p=0.148). Similarly, smokers did not differ significantly from non-smokers according to age (p=0.443), gender (p=0.274), rheumatoid factor positivity (p=0.231), anti-citrullinated protein antibody positivity (p=0.754) or seropositivity (p=0.163). In this study, we found no association between smoking status and disease activity, seropositivity, age or gender in rheumatoid arthritis patients. Furthermore, disease activity was not related to age, gender or seropositivity. Additional studies on the effects of smoking on rheumatoid arthritis activity are needed.


Asunto(s)
Artritis Reumatoide , Fumar , Anciano , Artritis Reumatoide/complicaciones , Artritis Reumatoide/epidemiología , Proteína C-Reactiva , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factor Reumatoide , Fumar/efectos adversos , Fumar/epidemiología
6.
Lijec Vjesn ; 138(1-2): 54-6, 2016.
Artículo en Croata | MEDLINE | ID: mdl-27290815

RESUMEN

Granulomatosis with polyangiitis (Wegener's granulomatosis) is one of the anti-neutrophil cytoplasmic anti-body-associated small vessel vasculitides. Upper and lower respiratory system and kidneys are most commonly affected. The disease is characterized by granulomatous inflammation of the respiratory tract and necrotizing vasculitis of small to medium-sized blood vessels. Most patients show involvement of more than one organ systems at the time of diagnosis, and constitutional symptoms may be present. In around a quarter of patients the disease is initially localised, with involvement of upper respiratory tract or lungs. We report a 21-year-old female patient with chronic rhinitis, saddle nose deformity and subglottic stenosis who presented with inspiratory stridor and impending respiratory failure. Initially, urgent tracheotomy was performed. The patient was diagnosed with granulomatosis with polyangiitis limited to upper respiratory tract. Treatment with glucocorticoids and methotrexate was followed by clinical improvement.


Asunto(s)
Glucocorticoides/administración & dosificación , Granulomatosis con Poliangitis , Metotrexato/administración & dosificación , Sistema Respiratorio , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Femenino , Granulomatosis con Poliangitis/sangre , Granulomatosis con Poliangitis/diagnóstico , Granulomatosis con Poliangitis/fisiopatología , Granulomatosis con Poliangitis/terapia , Humanos , Inmunosupresores/administración & dosificación , Mucosa Nasal/patología , Sistema Respiratorio/patología , Sistema Respiratorio/fisiopatología , Resultado del Tratamiento , Adulto Joven
7.
Reumatizam ; 63 Suppl 1: 18-22, 2016.
Artículo en Croata | MEDLINE | ID: mdl-29624040

RESUMEN

Rheumatic diseases are chronic inflammatory disorders with ongoing inflammation that causes tissue damage. Inflammatory and damaged cells synthetize and release many diff erent intracellular substances which can activate highly specialized subsets of primary sensory neurons called nociceptors. Some of these proinflammatory mediators directly activate the nociceptor terminal and produce pain (such as hydrogen ion, adenosine triphosphate, and bradykinin), and others sensitize the terminal so that it becomes hypersensitive to subsequent and non-noxious stimuli (such as prostaglandin E2 and bradykinin). Acute pain has a protective role since it induces behavior that promotes healing and recovery, such as immobilization which limits tissue damage. Chronic pain is unhelpful pain that tends to be out of proportion to the actual tissue damage and persists long after the tissues have healed, so that the pain becomes the problem rather than the tissues of origin. Chronic pain affects the physical and mental status and causes impairment of quality of life as well as work disability. For rheumatologists the assessment and treatment of pain is a very important integral part of patient care, and understanding the etiology and pathogenesis of pain is necessary to fi nd adequate modalities of treatment to prevent suffering.


Asunto(s)
Dolor/etiología , Enfermedades Reumáticas/complicaciones , Humanos , Enfermedades Reumáticas/patología
8.
Rheumatol Int ; 35(12): 2047-57, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26059944

RESUMEN

The purpose of the study was to examine whether rheumatoid arthritis (RA) patients have higher prevalence of metabolic syndrome (MetS) than osteoarthritis (OA) patients in association with a higher level of chronic systemic inflammation in rheumatoid arthritis. A total of 583 RA and 344 OA outpatients were analyzed in this multicentric study. Metabolic syndrome was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria. A 1.6-fold higher prevalence of MetS was found in patients with OA compared with the RA patients. Among the parameters of MetS, patients with OA had significantly higher levels of waist circumference, systolic blood pressure, fasting blood glucose and triglycerides, whereas HDL cholesterol and diastolic blood pressure values were similar in both groups of patients. Higher values of inflammatory markers [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] in MetS than in non-MetS patients and higher prevalence of MetS in patients with CRP level ≥5 mg/L in both RA and OA patients were found. In multivariate logistic regression analysis, significant predictors of MetS were type of arthritis (OA vs. RA; OR 2.5 [95 % CI 1.82-3.43]), age (OR 1.04 [95 % CI 1.03-1.06]) and ESR (OR 1.01; [95 % CI 1.00-1.01]). The significant association between OA and MetS was maintained in the regression model that controlled for body mass index (OR 1.87 [95 % CI 1.34-2.61]). The present analysis suggests that OA is associated with an increased risk of MetS, which may be due to a common underlying pathogenic mechanism.


Asunto(s)
Artritis Reumatoide/epidemiología , Síndrome Metabólico/diagnóstico , Síndrome Metabólico/epidemiología , Osteoartritis/epidemiología , Anciano , Artritis Reumatoide/metabolismo , Glucemia/metabolismo , Presión Sanguínea/fisiología , Comorbilidad , Estudios Transversales , Humanos , Lípidos/sangre , Síndrome Metabólico/metabolismo , Persona de Mediana Edad , Osteoartritis/metabolismo , Prevalencia , Circunferencia de la Cintura/fisiología
9.
Croat Med J ; 56(3): 280-9, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26088853

RESUMEN

AIM: To evaluate the role of gray-scale and color duplex-Doppler ultrasound (CDUS) in diagnosis of changes of hand joints and assessment of treatment efficacy in patients with rheumatoid arthritis (RA) by comparing qualitative and quantitative US parameters with clinical and laboratory indicators of disease activity. METHODS: Ulnocarpal (UC), metacarpophalangeal (MCP), and proximal interphalangeal (PIP) joints in 30 patients with RA were examined by gray-scale and CDUS before and after six months of treatment. Morphologic and quantitative Doppler findings (synovial thickness, effusion quantity, vascularization degree, resistance index, velocities) were compared with clinical indicators of disease progression: disease activity score (DAS 28), Health Assessment Questionnaire (HAQ), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C reactive protein (CRP). RESULTS: Clinical indicators changed significantly after treatment: ESR from 38.1±22.4 mm/h to 27.8±20.9 mm/h (P=0.013), DAS 28 from 5.47±1.56 to 3.87±1.65 (P<0.001), and HAQ from 1.26±0.66 to 0.92±0.74 (P=0.030), indicating therapeutic effectiveness. In all MCP and UC joints we observed a significant change in at least one US parameter, in 6 out of 12 joints we observed a significant change in ≥2 parameters, and in 2 UC joints we observed significant changes in ≥3 parameters. The new finding was that the cut-off values of resistance index of 0.40 at baseline and of 0.55 after the treatment indicated the presence of active disease and the efficacy of treatment, respectively; also it was noticed that PIP joints can be omitted from examination protocol. CONCLUSION: Gray scale and CDUS are useful in diagnosis of changes in UC and MCP joints of patients with RA and in monitoring the treatment efficacy.


Asunto(s)
Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/diagnóstico , Articulaciones de la Mano/diagnóstico por imagen , Ultrasonografía Doppler/métodos , Adolescente , Adulto , Anciano , Sedimentación Sanguínea , Proteína C-Reactiva/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factor Reumatoide/sangre , Resultado del Tratamiento , Adulto Joven
10.
Reumatizam ; 62(2): 16-21, 2015.
Artículo en Croata | MEDLINE | ID: mdl-26882799

RESUMEN

INTRODUCTION: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing low bone mass (LBM) or osteoporosis, either because of the disease itself or due to its treatment. Osteoporosis and osteoporotic fractures significantly contribute to morbidity and mortality. We aimed to determine the associations of bone mineral density (BMD) changes with the duration of SLE, age, gender, and glucocorticoid treatment in SLE patients treated at our Department. PATIENTS AND METHODS: BMD measurements of the lumbar spine and total hip were performed by dual-energy X-ray absorptiometry (DXA). Osteoporosis and LBM were determined according to the 1994 World Health Organization definition. In the statistical analysis, the independent Mann-Whitney U test and Tukey post-hoc testing were used. RESULTS: The study included 48 SLE patients (44 female and 4 male), with a mean age of 45.8 years and an average SLE duration of 9.8 years. Osteoporosis was diagnosed in 21%, and LBM in 15% of the patients. The mean ages of the subgroups with normal BMD, LBM, and osteoporosis were 41.1, 47.6, and 59.0 years, respectively. Variant analysis showed a statistically significant correlation between age and BMD (p < 0.05). The duration of SLE was significantly shorter in patients with normal BMD (7.3 years), compared to patients with LBM (16.1 years) and osteoporosis (12.9 years) (p < 0.05). Nearly all patients (47 of 48) were on long-term treatment with glucocorticoids. One third (33.3 %) of patients did not take vitamin D3, and 56.3 % did not take calcium supplements. CONCLUSION: The etiopathogenesis of decreased BMD in SLE patients is multifactorial and includes both traditional and SLE-related risk factors. In our group of SLE patients age and glucocorticoid treatment were the major risk factors for LBM. Timely prevention and treatment of LBM and osteoporosis in SLE patients, according to current knowledge, are essential for reducing morbidity and mortality.


Asunto(s)
Densidad Ósea , Lupus Eritematoso Sistémico/complicaciones , Osteoporosis/complicaciones , Adulto , Femenino , Glucocorticoides/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Osteoporosis/tratamiento farmacológico , Fracturas Osteoporóticas/complicaciones , Factores de Riesgo
11.
Reumatizam ; 62(1): 12-9, 2015.
Artículo en Croata | MEDLINE | ID: mdl-27024887

RESUMEN

Golimumab is a human monoclonal antibody which inhibits tumor necrosis factor-alpha (TNF-α) and is approved for the treatment of inflammatory arthritides (rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis) when the conventional non-pharmacological and pharmacological therapies fail to cause remission or low disease activity. In this retrospective study there were included patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis who were treated in Croatia with golimumab, from June 2011 to June 2013. included and these retrospective data are compared with similar data from clinical trials and other available databases. Standard variables of disease activity and functional ability were observed. Results demonstrated significant efficacy of golimumab regarding lowring the disease activity and imrpving functional ability in pateints with these inflammatory rherumatic disease. In conclusion, in this retrospective study during two years treatment golimumab showed efficacy in decreasing disease activity and imrpove functional ability in patiemts with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Espondilitis Anquilosante/tratamiento farmacológico , Artritis Psoriásica/fisiopatología , Artritis Reumatoide/fisiopatología , Croacia , Humanos , Estudios Retrospectivos , Espondilitis Anquilosante/fisiopatología
13.
Acta Med Croatica ; 68(3): 295-8, 2014 Jun.
Artículo en Croata | MEDLINE | ID: mdl-26016221

RESUMEN

Raynaud's phenomenon is a common phenomenon in the general population. It most commonly occurs in healthy individuals, in whom there is no associated illness or any other cause of Raynaud's phenomenon (primary or idiopathic Raynaud's phenomenon). Secondary Raynaud's phenomenon is common with rheumatic diseases (systemic sclerosis, systemic lupus erythematosus, primary Sjögren's syndrome, mixed connective tissue disease, etc.), occlusive vascular diseases, hematologic disorders, use of vibrating tools and use of some medications, and rarely with malignancy. We report on a patient who presented with a three-week history of painful Raynaud's attacks, which was the reason for seeking assistance of internists in emergency clinic. Upon admission to the hospital and diagnostic work-up, adenocarcinoma of the lung was found. Antinuclear antibodies (ANA), anti-dsDNA antibodies, anticardiolipin IgM and IgG antibodies were present in a lower titer. It is known that rheumatoid factor or ANA characteristic of rheumatic disease are often present in patients with paraneoplastic rheumatic syndromes, which can lead to wrong conclusions about the possible systemic connective tissue diseases and ultimately delay the correct diagnosis. The first appearance of Raynaud's phenomenon as an isolated symptom in people older than 50, with painful signs of ischemia, as in our patient, or the occurrence of asymmetric grasping fingers, especially in men, regardless of the presence of RF, ANA, anti-dsDNA or other autoantibodies, requires broader diagnostic evaluation for malignancy.


Asunto(s)
Adenocarcinoma/diagnóstico , Anticuerpos Antinucleares/sangre , Neoplasias Pulmonares/diagnóstico , Enfermedad de Raynaud/sangre , Enfermedad de Raynaud/diagnóstico , Adenocarcinoma/complicaciones , Progresión de la Enfermedad , Diagnóstico Precoz , Humanos , Neoplasias Pulmonares/complicaciones , Masculino , Persona de Mediana Edad , Enfermedad de Raynaud/etiología
14.
Lijec Vjesn ; 136(7-8): 228-31, 2014.
Artículo en Croata | MEDLINE | ID: mdl-25327013

RESUMEN

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare diseases, with the average of 30 new cases per million inhabitants per year. Their main characteristic is systemic involvement with necrosis of the vessel walls (histological changes showing necrosis of the media and inflammation of adventitia and intima). In some forms granulomas may be found surrounding the vessels. ANCA-associated vasculitides include granulomatosis with polyangiitis (GPA, previously called Wegener's), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, previously called Churg-Straus). Honorific eponyms are now changing to a disease-descriptive or etiology-based nomenclature. ANCA-associated vasculitides are a distinctive group of vasculitides because they dominantly involve small sized vessels, sometimes even medium sized vessels, are associated with antineutrophil cytoplasmic antibodies with high risk of developing glomerulonephritis and respond well to immunosuppresion with cyclophosphamide.


Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/fisiopatología , Síndrome de Churg-Strauss/fisiopatología , Femenino , Granulomatosis con Poliangitis/fisiopatología , Humanos
15.
Lijec Vjesn ; 136(1-2): 22-4, 2014.
Artículo en Croata | MEDLINE | ID: mdl-24720151

RESUMEN

Visceral leishmaniasis or kala-azar is a systemic infectious vector-borne disease caused by protozoa Leishmania donovani and Leishmania infantum that are transmitted to mammalian hosts by sand flies. It occurrs sporadically in endemic areas, including Mediterranean basin. Southern coastal territories of Croatia have been recognized as the foci of the disease. Dogs are the main reservoir of human infection. Clinical features include prolonged fever, malaise, hepatosplenomegaly, pancytopenia and inversion of albumin-globulin ratio. If left untreated, the disease causes death in majority of cases. We report a 47-year-old Croatian patient who was admitted to hospital with 2-month history of fever of unknown origin. Based on bone marrow aspirate findings and positive serological tests, the diagnosis of visceral leishmaniasis was established. We also considered secondary hemophagocytic lymphohystiocytosis in the differential diagnosis. After a 4-week treatment with sodium-stibogluconate clinical remission was achieved as well as complete recovery of hematopoesis. The aim of our case-report is to stress the importance of considering visceral leishmaniasis in patients with longstanding fever in endemic areas.


Asunto(s)
Fiebre de Origen Desconocido/parasitología , Leishmaniasis Visceral/diagnóstico , Animales , Antiprotozoarios/uso terapéutico , Médula Ósea/parasitología , Croacia , Diagnóstico Diferencial , Perros , Humanos , Leishmania infantum/aislamiento & purificación , Leishmaniasis Visceral/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
16.
Reumatizam ; 61(2): 31-6, 2014.
Artículo en Croata | MEDLINE | ID: mdl-25427392

RESUMEN

Comorbidity in rheumatoid arthritis (RA) patients significantly impairs and limits management of primary disease, decreases general quality of life, and worsens outcomes. Cardiovascular comorbidity is the leading cause of excess mortality in RA patients, which is up to two times higher compared to the general population. Infections, pulmonary disease and malignant diseases also contribute to excess mortality, while fatigue, depression and osteoporosis are related to decreased quality of life. Adequate management of RA patients should therefore, besides tight control of disease activity, also include comorbidity screening and management. This approach should improve both RA and comorbidity related outcomes.


Asunto(s)
Artritis Reumatoide/complicaciones , Artritis Reumatoide/mortalidad , Enfermedades Cardiovasculares/complicaciones , Humanos , Neoplasias/complicaciones , Osteoporosis/complicaciones , Calidad de Vida
17.
Reumatizam ; 61(1): 40-5, 2014.
Artículo en Croata | MEDLINE | ID: mdl-25509835

RESUMEN

Henoch-Schönlein purpura (HSP) is the most common systemic vasculitis in children, while it is rare in adults. Typical clinical manifestations include palpable purpura without thrombocytopenia and/or coagulopathy, arthritis/arthralgia, abdominal pain, and/or renal involvement. In adulthood the disease tends to be more serious than in children, with renal manifestations developing over a period of several days to one month after initial symptoms. In this article we present a 22-year-old female patient with cutaneous vasculitis and arthralgia, in whom renal disease developed 8 weeks after disease onset with microscopic hematuria and proteinuria in urinalysis. Renal biopsy subsequently performed revealed focal necrotising glomerulonephritis with IgA deposits. The patient was treated with high dose methylprednisolone followed by gradual tapering, which induced complete remission of the disease. In conclusion, patients with HSP should be carefully monitored for systemic involvement, since serious renal disease can develop even as late as two months after disease onset.


Asunto(s)
Glomerulonefritis/complicaciones , Vasculitis por IgA/complicaciones , Antirreumáticos/uso terapéutico , Femenino , Glomerulonefritis/tratamiento farmacológico , Humanos , Vasculitis por IgA/tratamiento farmacológico , Metilprednisolona/uso terapéutico , Factores de Tiempo , Adulto Joven
18.
Rheumatol Int ; 33(5): 1185-92, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-22965673

RESUMEN

In this study, we compare the prevalence of arterial hypertension (HT) in rheumatoid arthritis (RA) and osteoarthritis (OA) patients, exposed to high- and low-grade chronic inflammation, respectively, to assess the possible association between chronic inflammation and HT. A total of consecutive 627 RA and 352 OA patients were enrolled in this multicentric study. HT was defined as a systolic blood pressure (BP) ≥ 140 and/or diastolic BP ≥ 90 mmHg or current use of any antihypertensive drug. Overweight/obesity was defined as body mass index (BMI) ≥ 25, and patients ≥65 years were considered elderly. The prevalence of HT was higher in the OA group than in the RA group [73.3 % (95 % CI, 68.4, 77.7) and 59.5 % (95 % CI, 55.6, 68.4) P < 0.001, respectively]. When the results were adjusted for age and BMI, the HT prevalence was similar in both groups [RA 59 % (95 % CI, 55.1, 63.8) OA 60 % (95 % CI, 58.4, 65.0)]. In both groups, the prevalence of HT was higher in the elderly and those who were overweight than in the younger patients and those with a BMI < 25. Overweight (BMI ≥ 25) and age ≥65 were independent predictors of HT in multivariate logistic regression model, which showed no association between HT and the disease (RA or OA). The results indicate a robust association of age and BMI with HT prevalence in both RA and OA. The difference in HT prevalence between RA and OA is due rather to age and BMI than to the features of the disease, putting into question specific association of HT with RA.


Asunto(s)
Presión Arterial , Artritis Reumatoide/epidemiología , Hipertensión/epidemiología , Osteoartritis/epidemiología , Factores de Edad , Anciano , Antihipertensivos/uso terapéutico , Presión Arterial/efectos de los fármacos , Artritis Reumatoide/diagnóstico , Índice de Masa Corporal , Croacia/epidemiología , Femenino , Humanos , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Obesidad/diagnóstico , Obesidad/epidemiología , Oportunidad Relativa , Osteoartritis/diagnóstico , Dimensión del Dolor , Prevalencia , Factores de Riesgo , Encuestas y Cuestionarios
19.
Reumatizam ; 60(2): 35-8, 2013.
Artículo en Croata | MEDLINE | ID: mdl-24979994

RESUMEN

Large vessel vasculitis includes Giant cell arteritis and Takayasu arteritis. Giant cell arteritis is the most common form of vasculitis affect patients aged 50 years or over. The diagnosis should be considered in older patients who present with new onset of headache, visual disturbance, polymyalgia rheumatica and/or fever unknown cause. Glucocorticoides remain the cornerstone of therapy. Takayasu arteritis is a chronic panarteritis of the aorta ant its major branches presenting commonly in young ages. Although all large arteries can be affected, the aorta, subclavian and carotid arteries are most commonly involved. The most common symptoms included upper extremity claudication, hypertension, pain over the carotid arteries (carotidynia), dizziness and visual disturbances. Early diagnosis and treatment has improved the outcome in patients with TA.


Asunto(s)
Arteritis de Células Gigantes/diagnóstico , Arteritis de Takayasu/diagnóstico , Factores de Edad , Arteritis de Células Gigantes/complicaciones , Arteritis de Células Gigantes/terapia , Humanos , Arteritis de Takayasu/complicaciones , Arteritis de Takayasu/terapia
20.
Reumatizam ; 60(1): 32-6, 2013.
Artículo en Croata | MEDLINE | ID: mdl-24003682

RESUMEN

Gluten-sensitive enteropathy or celiac disease is a chronic small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals. Although the disease may manifest itself at any age, it occurs mostly in either early childhood or in the third or fourth decade of life. Malabsorption syndrome as a typical clinical feature is commonly absent. Patients may exhibit minor gastrointestinal complaints, as well as numerous extraintestinal manifestations. We report a 43-year-old female patient with mi gratory arthralgias as the leading symptom, fatigue, sideropenic anemia and mild intermittent diarrhoea, who was diagnosed with gluten-sensitive enteropathy. Four months after introduction of gluten-free diet the patient reported no arthralgias, and complete clinical response was achieved. The aim of our case-report was to show that migratory arthralgias can be an extraintestinal manifestation of gluten-sensitive enteropathy. Unexplained articular complaints should raise clinical suspicion of celiac disease.


Asunto(s)
Artralgia/etiología , Enfermedad Celíaca/diagnóstico , Adulto , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/dietoterapia , Diarrea/etiología , Fatiga/etiología , Femenino , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA